Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003525325 | SCV004295779 | pathogenic | Bardet-Biedl syndrome | 2023-07-03 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with BBS2-related conditions. This variant is present in population databases (rs753557069, gnomAD 0.003%). This sequence change creates a premature translational stop signal (p.Tyr103Metfs*14) in the BBS2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BBS2 are known to be pathogenic (PMID: 11285252, 20177705, 24608809, 26518167). For these reasons, this variant has been classified as Pathogenic. |